NHS will pay for last chance lung cancer pill: Hundreds set to benefit from tumour-busting drug that uses a patient's genetics to target the illness

Hundreds of lung cancer patients are to benefit from a revolutionary tumour-busting drug after it was approved for use on the NHS.
Osimertinib is one of the first in a new generation of precision medicines that use patients’ genetics to target the individual characteristics of their illness.
The drug, made by British drugs firm AstraZeneca, last night became the first to be approved for the revamped Cancer Drugs Fund.
The daily tablets target non-small-cell lung cancer tumours among people who have a specific genetic mutation which means they have stopped responding to earlier treatments.... read more

4 October 2016 in Health, Views: 51
Source: Daily Mail

News Widget for Webmasters

Realtime News


Mo Tu We Th Fr Sa Su
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30